ALEXANDER N. GREINER, M.D., FAAAAI

Private Practice 2003 - Present
Co-Director, Allergy & Asthma Medical Group and Research Center, A P.C.
5776 Ruffin Road
San Diego, California 92123
(858) 292-1144 ph
(858) 268-5145 fx

Assistant Clinical Professor, Department of Medicine
University of California, San Diego, School of Medicine

California Medical License Number: A77327

EDUCATION:

1993 Undergraduate: Columbia College, New York, NY, B.A. Premed with French minor
1994 Graduate School: Boston University School of Medicine, Boston, MA: M.A. in Medical Sciences
1998 Medical School: SUNY Health Science Center at Syracuse, Syracuse, NY: M.D. degree
1999 Internship: Winthrop University Hospital
2001 Residency: Winthrop University Hospital, Categorical Internal Medicine
2003 Fellowship: University Of California San Diego, Allergy and Clinical Immunology

BOARD CERTIFICATIONS & LICENSURE:

American Board of Internal Medicine, 2002-current
American Board of Allergy and Immunology, 2003-current
California Medical License, 2001-current
DEA license, current

HONORS/AWARDS:

John F. Aloia award for academic achievement, scholarship and clinical excellence

SOCIETY MEMBERSHIPS:

Fellow, American Academy of Allergy, Asthma and Immunology, 2010 to present
Member since 2001
Sinusitis committee, 2004 to 2006
San Diego Allergy Society, 2001 to present
Vice President, 2008 to 2010
President, 2010 to 2011
California Medical Association, 2001 to present
San Diego County Medical Society, 2004 to present
Western Society of Asthma, Allergy & Immunology, 2007 to present
World Allergy Organization
Allergic Rhinitis Working Group, 2011 to present

EDITORIAL BOARDS:

International Archives of Allergy and Immunology, 2005 to 2007

Reviewer:

Current Drug Safety, 2011 to present

OTHER ACTIVITIES:

Annual volunteer at ALA sponsored SCAMP CAMP in Julian, CA, 2002-2006, 2008
Teaching fellows, University of California, San Diego 2003 to present
Teaching Internal Medicine Residents, University of California, San Diego 2007 to present

PUBLICATIONS: ALEXANDER N. GREINER, MD

1. Greiner AN, Hellings PW, Rotiroti G, Scadding GK. Allergic rhinitis. Lancet. 2011 Dec 17;378(9809):2112-22.
2. Greiner AN, Meltzer EO. Overview of the treatment of allergic rhinitis and nonallergic rhinopathy. Proc Am Thorac Soc 2011;8:121-131.
3. Greiner A. Allergic rhinitis. BMJ Publishing Group point-of-care web site 2010, 2011
4. Greiner AN. Allergic Rhinitis: considerations for treatment. BMJ Learning 2008. With annual updates http://learning.bmj.com/learning/main.html.
5. Greiner AN. Allergic Rhinitis. In: Graham JM, Scadding GK, Bull PD, editors. Pediatric ENT. Germany: Springer; 2007. p. 295-306.
6. Greiner AN, Meltzer EO. Pharmacologic rationale for treating allergic and nonallergic rhinitis. J Allergy Clin Immunol 2006; 118: 985-96.
7. Greiner AN. Allergic Rhinitis: Impact of the Disease and Considerations for Management. Med Clin N Am 2006; 90: 17-38.
8. Greiner AN, Wanderer AA, Hoffman HM. Inflammatory Mechanisms involved in Familial Cold Autoinflammatory Syndrome. J Allergy Clin Immunol. 2003; 111 (2): 316-7.
9. Greiner AN, Mangat R, Kadota RP, Bastian JF. Successful Treatment of the accelerated Phase of Chediak-Higashi Disease with a Combination of Splenectomy and G-CSF. Annals of Allergy, Asthma and Immunology. 2003; 90 (1); 159.
10. Greiner AN, Davis-Lorton M, Fonacier LS. A Cross-Sectional Evaluation of Risk Factors for Developing Latex Allergies at a Tertiary Care Facility. J Allergy Clin Immunol. 2001; 107 (2): 132.
11. Greiner AN, Fonacier LS, Davis-Lorton M, Gianelli B. Impact of Latex Allergy at Winthrop University Hospital
12. Anbar RD, Greiner AN, Holota PS, Siegel AG. The Association of Mouthbreathing and Asthma in a Pediatric Population. Am J Resp Crit Care Med. 1998; 157(3), 645.
13. "Ascorbate and Infectious Diseases." Thesis. Mentor: Joseph Vitale, M.D. Department of Pathology, Boston University School of Medicine. 1994.

MEDIA & INTERVIEWS: ALEXANDER N. GREINER, MD

1. KUSI News. Update on fall allergies. Aired October 11th, 2003
2. Fox News at 10. Update on the health effects of the wildfires. Aired November 7, 2003
3. Fox News at 10. Update on spring allergies. Aired April 2005.
4. Choose the Right Allergy Treatment. Consumer Reports on Health, September 2007; 8-9.

PRESENTATIONS: ALEXANDER N. GREINER, MD

1. California Employee Pharmacist Association. Update on Allergic Rhinitis. San Diego, C.A. October 26, 2003
2. Greiner AN, Welch MJ. Astra-Zeneca air. Solve the case: Vocal cord dysfunction. January 17, 2004
3. Greiner AN, Welch MJ. Astra-Zeneca air. Solve the case: Ademoidal Hypertrophy. May 10, 2004
4. Lecturer to American Lung Association for the National Asthma Education course. September 25, 2004.
5. "Asthma Devices." CME talk, sponsored by Scripps Mercy Hospital. November 2, 2004.
6. "Update in Asthma Management and COPD Patients, Disease Control & Improving Quality of Life." 5th Annual CME Conference, Temecula Creek Inn, Temecula, California, November 7, 2004.
7. "Triage of the Allergic Rhinitis Patient and an Updated on Treatment Options." Sanofi-Aventis, Pacifica Del Mar, Del Mar, California, June 23, 2005.
8. "Controlling Asthma and an Updated on the Delivery Devices." Sharp Community Medical Group, 6th Annual CME Conference, Indian Wells, CA October 22, 2005.
9. "Anaphylaxis in Schools." California School Nurses Organization, Children's Hospital, San Diego, CA, March 18, 2006.
10. "Asthma, Allergies & Sleep." Current Concepts in Pediatric Allergy and Otolaryngology-Children's Hospital CME. San Diego, CA, May 28, 2006.
11. "Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Health Care Professional." The Network for Continuing Medical Education, Anaheim, California, June 14, 2008.
12. "Allergic Rhinitis and Its Comorbidities: A Serious Challenge to the Health Care Professional." Network for Continuing Medical Education (NCME) and Primary Care Network (PCN), Brooklyn, New York, October 14, 2008.
13. "Controlling Symptoms and Improving Quality of Life." Nurse Practitioners 21st Annual Conference, Houston, Texas, September 12, 2009.
14. "Managing Allergic Rhinitis." California's Physician Assistants 33rd Annual Conference, Palm Springs, California, September 24, 2009.
15. "An Update on Allergic Rhinitis." Network for Continuing Medical Education (NCME) and Primary Care Network (PCN), Anaheim, California, November 14, 2009.

RESEARCH: ALEXANDER N. GREINER, MD

Studies conducted at UCSD:

1. A one-year randomized, double-blind, placebo and active-controlled parallel design safety and efficacy comparison of COMBIVENT HFA inhalation aerosol to COMBIVENT® (CFC) inhalation aerosol in patients with COPD.
2. A randomized, double-blind, parallel group, comparative trial of salmeterol/fluticasone propionate combination product 50/100mcg diskus inhaler BID versus fluticasone propionate 250mcg diskus inhaler BID in adolescents & adults with moderate persistent asthma.
3. A randomized, double-blind, double-dummy, parallel-group 12-week comparative trial of salmeterol/fluticasone propionate combination product 50/100mcg BID via the diskus inhaler versus oral montelukast 10mg QD in adolescents and adults with persistent asthma.
4. A randomized, double-blind, placebo-controlled, parallel-group, 12-week trial evaluating the efficacy and safety of the fluticasone propionate/salmeterol DISKUS combination product 250/50mcg once daily versus fluticasone propionate/salmeterol DISKUS 250mcg once daily versus placebo in symptomatic adolescent and adult subjects with asthma that is not controlled on short acting beta2-agonists.
5. A randomized, double-blind, double-dummy, parallel-group, comparative, clinical trial evaluating fluticasone propionate/salmeterol xinafoate (250/50 mcg BID via DISKUS) to ipratropium/bromide/albuterol (36 mcg/206 mcg QID) inhalation aerosol in subjects with chronic obstructive pulmonary disease (COPD).

Studies conducted at Allergy and Asthma Medical Group and Research Center:

6. A multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the long-term effects of (salmeterol/fluticasone propionate seretide/viani/advair) 50/500 ug BD, salmeterol 50 ug BD and fluticasone propionate 500 ug BD, all delivered via the Diskus/Accuhaler Inhaler, on the survival of subjects with chronic obstructive pulmonary disease (COPD) over 3 years of treatment.
7. Feasibility of retinoic acid treatment in emphysema (FORTE).
8. A phase III double-blind, placebo-controlled, parallel-group, multicenter efficacy, safety and dose response study of ciclesonide metered dose inhaler 100ug/day, 200ug/day, and 400ug/day (ex-valve) administered once daily for 12 weeks in the treatment of mild to moderate persistent asthma in adolescents and adults.
9. A multicenter, randomized, double-blind, double-dummy, parallel group, 16 week comparison of asthma control in adolescents and adults receiving either fluticasone propionate/salmeterol DISKUS combination product 100/50mcg BID, fluticasone propionate DISKUS 100mcg BID, salmeterol xinafoate DISKUS 50 mcg BID or oral montelukast 10 mg QD.
10. 12 weeks treatment with 250 mg roflumilast versus placebo in patients with asthma.
11. A twelve-week randomized, double-blind, double-dummy, placebo- and active-controlled study of SYMBICORT™ pMDI administered once daily in adults and adolescents with asthma – STEM.
12. A randomized, double-blind, parallel-group multicentre efficacy and safety phase llB pilot study of esomeprazole 40 mg twice daily versus placebo twice daily in adult asthmatics treated for 4 months.
13. A study of avelox for treatment of elderly patients with community acquired pneumonia (the CAP study).
14. A multi-center, randomized, double-blind, parallel group, 40-week comparison of asthma control using bronchial hyperresponsiveness as an additional guide to long-term treatment in adolescents and adults receiving either fluticasone propionate/salmeterol DISKUS Bill or

fluticasone propionate DISKUS BID (or placebo BID if asymptomatic).

15. A multi-center, randomized, double-blind, double-dummy, parallel group, 8 week comparison of salmeterol xinafoate versus ipratropium bromide versus salmeterol xinafoate plus ipratropium bromide versus placebo in subjects with chronic obstructive pulmonary disease.
16. A phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, dose comparison study of the efficacy and safety of oral 25 mg, 50 mg, 75 mg OPC-6535 and placebo in the treatment of patients with chronic obstructive pulmonary disease.
17. Inhaled corticosteroid replacement study: efficacy and safety of Ro 27-2441 in moderate persistent asthma--Phase II.
18. Dose-ranging study of Ro 27-2441 in patients with persistent asthma not treated with inhaled corticosteroids--Phase II.
19. Efficacy and safety of inhaled human insulin (Exubera®) compared with subcutaneous human insulin in the therapy of adult subjects with type 1 or type 2 diabetes mellitus and chronic asthma: a one-year, multicenter, randomized, outpatient, open-label, parallel-group comparative trial.
20. Efficacy and safety of inhaled human insulin (Exubera®) compared with subcutaneous human insulin in the therapy of adult subjects with type 1 or type 2 diabetes mellitus and chronic obstructive pulmonary disease: a one-year, multicenter, randomized, outpatient, open-label, parallel-group comparative trial.
21. A phase II, multicenter, randomized, double-blind, placebo-controlled parallel group dose finding study evaluating the safety and efficacy of infliximab administration in symptomatic subjects with moderate to severe chronic obstructive pulmonary disease (COPD).
22. A multicenter, parallel study comparing the efficacy and safety of PULMOCORT RESPULES® (budesonide inhalation suspension) at 0.5 mg, QD, 1.0 mg QD, 1.0 BID, 2.0 BID and PULMICORT TURBUHALER ® (budesonide) at 400 mcg BID in adolescents (12 Years of Age and Older) and adults with moderate to severe asthma
    #SD-004- 0764
23. A parallel-group study investigating the clinical effect of L-000888839 in patients with seasonal allergic rhinitis – a pilot study during the fall season
    #005
24. A 40-week comparison of asthma control using bronchial hyperresponsiveness as an additional guide to long term treatment in adolescents and adults receiving either fluticasone propionate/salmeterol DISKUS BID or fluticasone propionate DISKUS BID (or placebo BID if asymptomatic)
    #SAM40086
25. A placebo-controlled, parallel-group study investigating the clinical effects of montelukast in patients with perennial allergic rhinitis
    #265
26. A twelve-week, active-controlled study of SYMBICORT® pMDI administered once daily in children and adolescents 6 to 15 years of age with asthma – SPROUT
    #SD-039-0725
27. A twelve-week, placebo- and active-controlled study of SYMBICORT® pMDI administered once daily in adults and adolescents with asthma – STEM
    #SD-039-0726
28. Qualitative assessment of patient diary questions to assess patient perception of the onset of effect if asthma medication using cognitive debrefing methodology.
    #A2-3269

RESEARCH: ALEXANDER N. GREINER, MD

29. 3-week, open-label, uncontrolled, multicenter study evaluating the functionality of the Foradil® Certihaler® device in patients with asthma
    #CFOR258F2304A
30. Efficacy and Safety of 200mcg QD or 200mcg BID Mometasone Furoate Nasal Spray (MFNS) vs. Amoxicillin vs. Placebo as Primary Treatment of Subjects with Acute Rhinosinusitis
    #P02692
31. A 1 year, randomized, double-blind, parallel-group, placebo-controlled, multicenter evaluation of efficacy, safety, pharmacokinetics and pharmacodynamics of omalizumab in children (6 - <12 years) with moderate-severe, persistent, inadequaltely controlled allergic asthma."
    #CIGE025AIA05
32. Psychometric Evaluation of Patient Satisfaction with Asthma Treatment
    #HRA 23-371B
33. A Multicenter, double-blind, placebo-controlled, randomized, parallel-group study to evaluate the clinical effect of oral Montelukast versus placebo during the allergy season in patients with seasonal aeroallergen sensitivity and chronic asthma which is also active during allergy season
    #289
34. A Multicenter, Randomized, Double-Blind Parallel Group Study of the Effects of Ciclesonide HFA-MDI 640 µg/day & beclomethasone HFA-MDI 640 µg/day on lens opacification in adult subjects w/ moderate to severe persistent asthma
    #XRP1526B – 3027
35. A Phase II Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Mast Cell Inhibitor, R-926112, in Patients with Symptomatic Seasonal Allergic Rhinitis in a Park Setting
    #R-926112-004
36. A randomized, controlled study of roflumilast (250 mcg and 500 mcg) versus placebo in patients with asthma. A 24-week, multicenter, multinational, double-blind, parallel group clinical study
    #BY217/M2-023
37. Ability to swallow with and without the aid of a pill cup in pediatrics subjects ages >6 to <12 years of age
    #M016455C/6001
38. A 3-week, open-label, uncontrolled, multicenter study evaluating the functionality of the Foradil® Certihaler® device in patients with asthma
    #CFOR258 F2306
39. 12 week study to assess the efficacy and safety of Symbicort® pMDI 160/4.5 µg x 2 actuations once-daily (QD) compared to Symbicort pMDI 80/4.5 µg x 2 actuations QD, Symbicort pMDI 80/4.5 µg x 2 actuations twice-daily (BID) and to budesonide pMDI 160 µg x 2 actuations QD in asthmatic subjects 12 years of age and older
    # D5896C0001
40. A placebo controlled study of the efficacy and safety of desloratadine vs. fexofenadine 180 mg. in the treatment of subjects with symptomatic seasonal allergic rhinitis (SAR)
    # P04053-11
41. Pediatric Questionnaire on Asthma Control: Initial Validation Study
    # GHO102199
42. Crossover study comparing the effect of L-000888839 with placebo & concomitant administration of L-000888839 plus montelukast in adults with chronic asthma

#008

43. A placebo-controlled, dose ranging study, to assess the efficacy and safety of 4 doses of QAB149 (50, 100, 200 & 400 ug) delivered via a multiple dose inhaler, and 1 dose of QAB149 (400 µg) delivered via a single dose inhaler, in adult and adolescent patients (12 – 75 years old inclusive) with stable, persistent asthma
    # CQAB149A2216
44. A four-week, placebo-controlled, study of ventolin HFA MDI delivered TID with facemask and valved holding chamber (Aerochamber Plus;) in subjects birth to<24 months in age with symptoms of bronchospasm (i.e. wheeze, cough, dyspnea or chest tightness) consistent with obstructive airways disease.
    # SB030001
45. A Phase 3 clinical trial designed to assess the efficacy and safety of ciclesonide applied as a nasal spray at three dose levels (100 mg, 200mg, or 25mg, once daily) in the treatment of perennial allergic rhinitis (PAR) in patients 6–11 years of age
    # BY9010/M1-403
46. Pharmacodynamics of the 88 mcg BID dose of the hydrofluoroalkane propellant formulation of inhaled fluticasone propionate following administration via the metered-dose inhaler in pediatric subjects 4 to 11 years of age with asthma
    # FAP 19052
47. A preference evaluation of Nasonex nasal spray (unscented vs. Flonase nasal spray (scented) in subjects with symptomatic allergic rhinitis (AR) single-dose cross-over
    # P04207
48. A placebo-and active-controlled (ciclesonide metered dose inhaler), dose range finding study of ciclesonide administered by dry powder inhaler (Ultrahaler®) in adult and adolescent patients with persistent asthma.
    # AVE2635A/2001
49. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X aqueous nasal spray 100 mcg for 4 weeks in adult and adolescent subjects (12 years of age) with perennial allergic rhinitis (PAR)
    #FFR30002
50. Randomized double–blind trial of Astelin® (azelastine hydrochloride) nasal spray compared to Zyrtec® (cetirizine) in patients with seasonal allergic rhinitis
    # MP 426
51. A randomized, double-blind, placebo-controlled study evaluating the effects of MN-001 in subjects with mild to moderate asthma
    #MN-001-CL-001
52. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of once-daily, intranasal administration of GW685698X aqueous nasal spray 50mcg and 100mcg for 12 weeks in pediatric subjects ages 2 to <12 years with perennial allergic rhinitis (PAR)
    #FFR30008
53. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X aqueous nasal spray 50mcg and 100mcg for 2 weeks in pediatric subjects Ages 2 to <12 years with seasonal allergic rhinitis (SAR)
    #FFR100010
54. randomized, double-blind, placebo-controlled, single-dose, 3-period crossover study to determine the effect of PLA-902 on exercise-induced bronchoconstriction

#PLA-902

55. Pilot efficacy and safety field trial of Desloratadine administered concomitantly with Oxybutynin, in subjects with seasonal allergic rhinitis and post-nasal drip
#SP4258
56. safety and efficacy of olopatadine hydrochloride nasal spray in pediatric patients
#C-04-20
57. Safety and bioequivalence of Triamcinolone Acetonide Nasal Spray compared w/ Nasacort AQ® nasal spray55 mcg in the relief of signs & symptoms of SAR
#CPL-404
58. A randomized, double-blind, placebo-controlled, parallel-group study of ciclesonide metered-dose inhaler administered at a daily dose of 160 ug either in a once-daily (160 ug qd) or a twice-daily (80 ug bid) regimen for 12 weeks in adults and adolescents with mild to moderate persistent asthma treated previously with inhaled corticosteroids
#XRP1526B/3030
59. A 3-week multicenter study investigating patient use and functionality of the Foradil® Certihaler® device in patients with asthma
#CFOR258F2309
60. A multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy of ciclesonide metered-dose inhaler at a daily dose of 160 µg administered either in a once-daily in the morning regimen (160 µg qd AM) for 16 weeks or in a 160 µg AM regimen for 12 weeks preceded by a twice-daily regimen (80 µg bid) for 4 weeks, or in an 80 µg bid regimen for 16 weeks, in adults and adolescents with mild to moderate persistent asthma not treated with steroids
#XRP1526B/3031
61. A phase II multi-center, randomized, double-blind, active and placebo--controlled 7 day study of mast cell inhibitor, R926112, in patients with symptomatic seasonal allergic rhinitis
#C-926112-005
62. Qualitative Research Into Asthma Control
#25-586A
63. A placebo- and active-controlled, parallel-group, dose-finding study of formoterol fumarate given by dry powder inhalation using the Ultrahaler® in adult and adolescent patients with persistent asthma
#AVE2635A-2003
64. Randomized, multicenter, crossover study to evaluate sensory attributes of olopatadine 0.6% nasal spray and Astelin® in patients with allergic rhinitis
#C-03-49
65. A Pilot Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair® DISKUS 250/50 mcg BID as Assessed by the Development of Laryngitis and Oropharyngeal Candidiasis in Adults with Mild Persistent Asthma
#NONE0-l-00081
66. A Phase III Multicenter Study to Demonstrate the Sensitivity and Specificity of Aridol (Mannitol) Challenge to Predict Bronchial Hyperresponsiveness as Manifested by a Positive Exercise Challenge in Subjects Presenting with Signs and Symptoms Suggestive of Asthma but Without a Definitive Diagnosis
#DPM-A-305
67. Childhood asthma control test: Longitudinal validation study.
8ADA106614
68. Efficacy and safety of combination Loratadine/Montelukast QD vs Pseudoephedrine and placebo in the treatment of subjects with seasonal allergic rhinitis.

#P04095

69. A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of once-daily intranasal administration of GW685698X aqueous nasal spray 100mcg for 6 weeks in adult and adolescent subjects 12 years of age and older with perennial allergic rhinitis (PAR).
    # FFR106080
70. Assessment of safety, tolerability, and pharmacokinetics of Zileuton Injection in patients with asthma.
    # CTI-04-C05-201
71. A multicenter, randomized, double-blind, triple dummy, placebo-controlled, parallel group, four-week study assessing the efficacy of fluticasone propionate aqueous nasal spray 200 mcg QD versus Montelukast 10 mg QD in adolescent and adult subjects with asthma and seasonal allergic rhinitis who are receiving Advair DISKUS® 100/50mcg BID or placebo BID.
    # ADA103578
72. Randomized, double-blind, placebo-controlled trial of the safety and efficacy of MP03-33 in patients with seasonal allergic rhinitis.
    # 430
73. Psychometric evaluation of the asthma control outcome and risk assessment measures.
    # A2-3721
74. A placebo-controlled, parallel-group, clinical trial designed to assess the safety and efficacy of Ciclesonide (200 mcg and 100 mcg, once daily) applied as a nasal spray for two weeks in the treatment of seasonal allergic rhinitis (SAR) in patients 6 to 11 years of age.
    # BY9010/M1-417
75. A Multi-Center, No Drug Treatment, Cross-Sectional Survey Study to Develop and Validate the Rhinitis Control Assessment Questionnaire (RCAQ) in Adult and Adolescent Subjects 12 Years of Age and Older with Non-Infectious Allergic Rhinitis
    # FFU 108675
76. Pilot polysomnography study in subjects with seasonal allergic rhinitis who report sleep disturbances and daytime somnolence
    # P04827
77. A Randomized, Cross-Over Design Study Evaluating a Traditional Paper Symptom Diary vs. the VOCEL® Mobile Diary in Subjects 12 years and Older with Mild to Moderate Persistent Asthma Receiving Alvesco® 80 µg BID
    # CICLE-L-01335
78. Double-Blind Multi-Centre, Placebo-Controlled, Clinical Study to Evaluate the Clinical Equivalence of 128 mcg of Budesonide Nasal Spray (Apotex Inc., Canada) vs. 128 mcg of Rhinocort Aqua® Nasal Spray (AstraZeneca, USA) for the Indication of Seasonal Allergic Rhinitis
    # BUDE-NASO-01NB01-CE
79. Psychometric Evaluation of the Asthma Control Outcome and Risk Assessment Measures
    # UBC A2-3721C
80. A multicenter, randomized, doublel-blind, placebo-controlled parallel group 8-week study to evaluate the efficacy and safety of chewable Montelukast when initiated at the start of the school year in pediatric patients with chronic asthma
    # 340-00
81. A Clinical Study to Evaluate the Safety and Efficacy of Claritin 12-Hour 5 mg Loratadine Tablet BID vs. Placebo Tablet in the Treatment of Allergic Rhinitis
    # CL2006-03

82. An eight week, randomized, double-blind, parallel group, multicenter trial comparing the efficacy and safety of Oral IPL512,602 to placebo in subjects with moderate to severe persistent asthma inadequately controlled on inhaled corticosteroids
    # 2002
83. A Patient Preference Evaluation Study of Fluticasone Nasal Spray and Fluticasone Propionate Aqueous Nasal Spray in Subjects with Allergic Rhinitis
    # FFU108556
84. A phase3, double-blind, placebo-controlled, multi-center, randomized study evaluating the safety and efficacy of SPRC-AB01, Tobramycin Solution for nasal inhalation, in post-surgical subjects with chronic rhinosinusitis
    # SPRC-AB01-003
85. Safety Study of Olopatadine Nasal Spray
    # C-05-69
86. A placebo-controlled, stratified, multicenter, 12-week study comparing the safety and efficacy of fluticasone and formoterol combination (FlutiForm™ 100/10µg or 250/10µg twice daily) in a single inhaler (SkyePharma HFA pMDI) with the administration of placebo of fluticasone (100/10µg or 250/10µg twice daily) and formoterol (10µg twice daily) alone in adult patients with asthma
    # 2028-3-004
87. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Multiple Dosing Regimens of Nasal CO2 in the Treatment of Allergic Rhinitis
    # C211
88. A randomized, double-blind, placebo controlled, 3 arm, parallel group, phase 2 study investigating the efficacy, tolerability and pharmacokinetics of MAP0010 in asthmatic children and adolescents
    # 0010-CL-P201
89. A double-blind placebo-controlled, randomized, parallel-group, single-site study of Nasonex Nasal Spray in subjects with mild-moderate obstructive sleep apnea-hyopnea (OSAHS) associated with perennial allergic rhinitis (PAR) using home-monitored cardio-respiratory methodology
    # P04726
90. Assessment of the content validity of the asthma Quality of Life Questionnaire (AQLQ) in patients with moderate to severe asthma
    # A2-4158 000
91. A Placebo-Controlled Study of the Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure
    # P04295
92. Inhaler Technique Evaluation for Pediatric Asthma
    # HRA 25-587A
93. A comparative study of the efficacy and tolerability of maintenance treatment of patients with mild/moderate persistent asthma with Asmanex Twisthaler 220 mcg QD PM versus "Asmanex" Placebo QD PM
    # P04654
94. Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 years or older) with Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy
    #BY9010/M1-490

RESEARCH: ALEXANDER N. GREINER, MD

95. Study to Evaluate Efficacy & Safety of GW685698X 200mcg BID GW685698X 200mcg & 400mcg QD in AM, & GW685698X 200mcg & 400mcg QD in the Evening Compared w/ Pbo for 8 Wks in Subjects 12+ w/persistant asthma
    #FFA106783
96. Placebo Controlled Study of Nasonex in the Treatment of Seasonal Allergic Rhinitis
    #P05067
97. A Randomized, Double-blind, Placebo-controlled, Multiple Dose Phase 2 Study to Determine the Safety and Efficacy of AMG 317 in Subjects With Moderate to Severe Asthma
    #20060161
98. Randomized, double-blind, placebo controlled trial of the safety and efficacy of MP03-36 and MP03-33 in patients with perennial allergic rhinitis
    #MP434
99. Active-Controlled Trial of the Safety and Tolerability of MP03-36 in Patients with Perennial Allergic Rhinitis
    #MP436
100. A Double-Blind, Placebo Controlled, Randomized Study to Evaluate the Clinical Effect of Oral Montelukast Versus Placebo in Persistent Asthma Which is Also Active During Allergy Seasons in Pediatric Patients with Seasonal Aeroallergen Sensitivity
    #336
101. A two-week, randomised, double-blind study assessing the Onset of Effect Questionnaire (OEQ) administered daily versus weekly in adult subjects (≥ 18 years of age) with mild to moderate asthma, receiving SYMBICORT® pMDI 80/4.5 µg x 2 actuations twice daily or budesonide HFA pMDI 80 µg x 2 actuations twice daily
    #D5896C00023
102. A double-blind, randomized, placebo-controlled, dose-ranging study to assess the efficacy and safety of ciclesonide HFA nasal aerosol in adult and adolescent patients 12 years and older with seasonal allergic rhinitis (SAR)
    #BY9010/M1-602
103. A 26-week placebo-controlled efficacy and safety study of mometasone furoate/formoterol fumarate combination formulation compared with mometasone furoate and formoterol monotherapy in subjects with persistent asthma previously treated with low-dose inhaled glucocorticosteroids
    #P04073
104. A 26-week placebo-controlled efficacy and safety study of mometasone furoate/formoterol fumarate combination formulation compared with mometasone furoate and formoterol monotherapy in subjects with persistent asthma previously treated with medium-dose inhaled glucocorticosteroids
    #P04334
105. A 26 week treatment, randomized, multi center, double blind, double dummy, parallel-group study to assess the safety of indacaterol (300 and 600 µg o.d.) in patients with moderate to severe persistent asthma using salmeterol (50 µg b.i.d.) as an active control
    #CQAB149B2338
106. Randomized, double-blind, placebo-controlled trial of the safety and efficacy of MP03-36 in patients with seasonal allergic rhinitis
    #439
107. A phase II, double-blind, placebo-controlled, multi-center, randomized study evaluating the safety and efficacy of SPRC-AB01, tobramycin solution for nasal inhalation, in post-surgical subjects with chronic sinusitis

SPRC-AB01

108. A randomized, double-blind, placebo-controlled study to evaluate the efficacy of Ziluten controlled-release (CR) tablets versus placebo in adult patients with asthma poorly controlled on moderate dose inhaled corticosteroids (ICS)
CTI-03-C07-401
109. Efficacy and safety of concurrent administration of mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray administered once daily (QD) vs. oxymetazoline twice daily (BID), mometasone furoate QD, and placebo in the treatment of subjects with seasonal allergic rhinitis
P04500
110. A randomized, double-blind, placebo-controlled, active comparator, one-week, cross-over, multicenter study to evaluate the efficacy and patient preference of nasal spray characteristics of once-daily, iIntranasal administration of 110mcg fluticasone furoate nasal spray and 200mcg fluticasone propionate nasal spray in adult subjects with seasonal allergic rhinitis
FFU105927
111. Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy (Bronchodilation) and Safety of 4 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (2 µg, 5 µg, 10 µg, 20 µg) Delivered by the Respimat® Inhaler in Patients with Asthma
#1222.6
112. Efficacy and safety of 200 mcg BID mometasone furoate nasal spray (MFNS) vs placebo as adjunctive treatment to antibiotics in relief of symptoms of acute bacterial sinusitis
P04824
113. A randomized, double blind, placebo controlled, parallel group, study investigating the safety and efficacy over 12 weeks treatment period of MAP0010 in asthmatic infants and children 12 months to 8 years of age
#0010-CL-P301
114. Validation of patient-reported outcomes in patients with moderate to severe asthma
#20070787
115. A randomized, double-blind, placebo-controlled, parallel-group study comparing the bioequivalence of Triamcinolone Acetonide Aqueous Nasal Spray (APOTEX, INC.) to that of Nasacort® AQ Nasal Spray (Aventis Pharmaceutical Products, Inc.) in the treatment of seasonal allergic rhinitis
TRIA-NASO-05RB02-CE
116. Test for respiratory and asthma control in kids (TRACK)
CTI-07-503
117. Safety and efficacy of olopatadine HCI nasal spray in 6-11 year old patients
C-07-01
118. Evaluation of successful use of a breath-actuated inhaler: a prospective, randomized, open-label, 2 arm parallel study
IXR-304-04-167
119. Exploratory study to measure the effect of Breathe Right Strips on nasal patency in healthy children
B3340547
120. Randomized, double-blind trial of MP29-02 nasal spray compared to placebo, azelastine hydrochloride nasal spray, and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis
#4002

RESEARCH: ALEXANDER N. GREINER, MD

121. A randomized, double blind, active controlled, phase 3 extension study investigating the safety and efficacy over 40 weeks of 2 doses of MAP0010 in asthmatic infants and children (aged 12 months to 8 years at enrollment into the MAP0010-CL-P301 study)
#0010-CL-P301X
122. A multi-center, randomized, double blind, placebo controlled parallel group study of the safety of Levocetirizine Dihydrochloride Oral Liquid Formulation b.i.d. dosing in children aged 2 to 6 years suffering from allergic rhinitis or chronic urticaria of unknown origin
A00426
123. A randomized, double-blind, double-dummy, placebo-controlled, parallel group, dose ranging study evaluating the efficacy and safety of GW642444M administered once daily and salmeterol 50mcg administered twice daily compared with placebo for 28 days in adolescent and adult subjects with persistent asthma.
B2C109575A
124. Placebo-controlled study of mometasone furoate nasal spray (MFNS) 200 mcg QD in the relief of nasal congestion associated with seasonal allergic rhinitis (SAR)
P05529
125. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study Comparing the Safety and Efficacy of MAP0010 (0.135 mg And 0.25 mg) with Placebo in 12-Month-Old to 8-Year-Old Children with Asthma
#0010-CL-P302
126. Two-Year Study to Evaluate the Ocular Safety of Once-Daily, Fluticasone Furoate Nasal Spray 110mcg in Adults & Adolescents 12 and Older w/ PAR
#FFR110537
127. A randomized, double-blind, active-controlled, Phase 3 extension study investigating the safety and efficacy over 40 weeks of 2 doses of MAP0010 in asthmatic children (12 months to 8 years old at the time of enrollment into the MAP0010-CL-P301 Study)
0010-CL-P301X
128. A double-blind, randomized, multicenter, cross-over evaluation of the sensory attributes of Olopatadine 0.6% and Azelastine 137 mcg nasal sprays in patients with allergic rhinitis (Sensory II)
SMA-08-21
129. Double-blind, randomized, placebo-controlled, multi-center, parallel group, dose-ranging study of MK0633 in adult patients with chronic asthma
007
130. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Nasal Carbon Dioxide in the Treatment of Seasonal Allergic Rhinitis
C215
131. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Ranging Study of Sublingual Immunotherapy (SLIT) in Adults Sensitized to the Standardized Allergenic Extract, Cat Hair (Felis domesticus)
ALI002-08
132. A double-masked, randomized, parallel group comparison of seasonal allergic rhinitis treatment with olopatadine 0.6% and azelastine 0.1% when treatments are used in combination with fluticasone propionate 50 mcg nasal spray
#SMA-08-23
133. A multicenter, randomized study starting with a 4-week, 2-way crossover double-blind treatment phase comparing the efficacy and safety of Combivent® CFC MDI to albuterol HFA MDI followed by a 4-week open-label Combivent Respimat® treatment phase when all

study drugs are used for symptom relief "as needed" in patients with moderate-to-severe asthma (GINA 2007 Treatment Steps 3 to 5)
#1012.57

134. A double-blind, randomized, placebo-controlled, parallel-group, multi-center, dose-range-finding study to assess the efficacy and safety of BDP HFA nasal aerosol in adult and adolescent patients (12 years and older) with seasonal allergic rhinitis (SAR)
BDP-AR-201
135. Safety of PATANASE® Nasal Spray in Patients with Perennial Allergic Rhinitis
C-08-32
136. Pulmonary safety of Staccato® Loxapine for inhalation in patients with asthma
AMDC-004-105
137. Randomized, double-blind trial of MP29-02 nasal spray compared to placebo, azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis
MP4006
138. A phase 4, multicenter, double-blind, randomized, placebo-controlled study of the safety and tolerance of Regadenoson in subjects with asthma or chronic obstructive pulmonary disease (COPD)
#3606-CL-3001
139. A double-blind, randomized, placebo-controlled, parallel group exploratory study of the safety and efficacy of JNJ-39758979 in the treatment of adults with persistent asthma
39758979ASH2001
140. A double-masked, randomized, multi-center study examining the safety and efficacy of olopatadine 0.6% and azelastine 137 mcg nasal sprays in a two-week vasomotor rhinitis trial
SMA-09-03
141. Phase 2b, randomized study to evaluate the efficacy and safety of subcutaneous MEDI-258 in adults with uncontrolled asthma
CP198
142. Randomized, double-blind, placebo-controlled trial of the safety and efficacy of mp03-36 (0.15% solution) and mp03-33 (0.10% solution) in children ages >6 to <12 with perennial allergic rhinitis
MP441
143. A randomized, double-blind, placebo controlled, multiple dose phase 2 study to determine the safety and efficacy of amg 853 in subjects with inadequately controlled asthma
#20080615
144. A 6- month randomized, double-blind, placebo-controlled, parallel group, efficacy and safety study of once daily ciclesonide HFA nasal aerosol (80 and 160 µg) in the treatment of perennial allergic rhinitis (PAR) in subjects 12 years and older
#060-633
145. A randomized, multi-center, parallel group, double blind, study to assess the safety of QMF Twisthaler® (500/400 µg)and mometasone furoate Twisthaler® (400 µg) in adolescent and adult patients with persistent asthma.
CQMF149A2210
146. A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to assess the efficacy and safety of different doses of indacaterol in adult patients with persistent asthma, using salmeterol as an active control.
#CQAB149B2357

RESEARCH: ALEXANDER N. GREINER, MD

147. A long-term, randomized, double-blind study of the safety, tolerability and efficacy of aclidinium bromide at two dosage levels when administered to patients with moderate to severe, stable chronic obstructive pulmonary disease.
#LAS-MD-35
148. A Randomized, Double-blind, Single-dose Efficacy Study of 0.05% Oxymetazoline Fine Mist Spray in Adult Subjects Suffering from Nasal Congestion.
#2010042
149. Qualitative Interviews with Patients who have Asthma.
#10-1378A
150. A 6-Month Open-Label, Long-Term Safety Extension Study of Once Daily Ciclesonide HFA Nasal Aerosol (160 μg) in The Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and Older.
#060-635
151. A 12-week Comparison of the Efficacy and Safety of Albuterol Spiromax versus Placebo in Subjects 12 years and older with Persistent Asthma.
ABS-AS-301
152. A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone Propionate Inhalation Powder 100mcg Twice Daily and Montelukast 10mg Daily compared with Placebo for 8 Weeks in Adolescent and Adult Subjects with Persistent Asthma while Treated with Short Acting $Beta_2$-agonist.
LPA112186
153. A Phase 2, double-blind, randomized, parallel-group, placebo-controlled, multicenter study, comparing budesonide pMDI 160 μg bid with placebo: a 6-week efficacy and safety study in children aged 6 to <12 years with asthma.
D589GC00001
154. A Phase III randomised, double-blind, placebo-controlled, parallel-group trial to evaluate efficacy and safety of tiotropium inhalation solution delivered via Respimat® inhaler (2.5 and 5 μg once daily) compared with placebo and salmeterol HFA MDI (50 μg twice daily) over 24 weeks in patients with moderate persistent asthma.
#204.418
155. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Clinical Study to Assess the Efficacy and Safety of BDP HFA Nasal Aerosol (320 mcg, once daily) in the Treatment of Perennial Allergic Rhinitis (PAR) in Adult and Adolescent Subjects (12 Years of Age and Older).
BDP-AR-302
156. A randomized, dose-ranging, placebo-controlled trial to evaluate the effects of phenylephrine HCl immediate release tables on nasal congestion in subjects with seasonal allergic rhinitis
CL2010-06
157. Psychometric evaluation of a novel questionnaire designed to assess patient satisfaction with and preference of intranasal corticosteroids administered via HFA aerosol or aqueous suspension used for the treatment of allergic rhinitis
#060-301
158. A prospective, open label, Assessment of the Albuterol ProAir HFA MDI integrated dose counter
ABM-AS-307
159. A randomized, double-blind, placebo-controlled, parallel-group study comparing the bioequivalence of ciclesonide nasal spray (APOTEX, Inc.) to that of Omnaris nasal spray (Sepracor, Inc.) in the treatment of seasonal allergic rhinitis

CICE-NASU-05SB03-CE

160. A randomized, placebo- controlled, parallel group study to assess the efficacy, safety, and pharmacokinetics of QAW039 in steroid-free patients with mild to moderate persistent asthma
CQAW039A2201
161. A randomized, double-blind, placebo-controlled, parallel-group, multi-center study to assess the efficacy and safety of BDP HFA Nasal Aerosol in pediatric subjects (6 to 11 years of age) with seasonal allergic rhinitis (SAR)
BDP-AR-305
162. A 12-week dose-ranging study to evaluate the efficacy and safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) administered twice daily compared with placebo in adolescent and adult subjects with persistent asthma uncontrolled on non-steroidal therapy
#FpS-AS-201
163. A multicenter, consumer product evaluation of a single dose of Phenylephrine HCI 30mg Extended Release Tablets (Sinus Comfort)
#CL2012-03
164. A randomized, placebo-controlled, dose-ranging, multi-centre trial of QAW039 (1- 450 mg p.o.) to investigate the effect on FEV_1 and ACQ in patients with moderate-to-severe, persistent, allergic asthma, inadequately controlled with ICS therapy
#CQAW039A2206
165. A 2-week randomized, double blind, placebo controlled, parallel group, safety and efficacy study of Ciclesonide Nasal Aerosol in subjects 6 to 11 years with seasonal allergic rhinitis
#060-305
166. Non-invasive neurostimulation of the Vagus Nerve for the relief of acute bronchoconstriction due to asthma
#BC-US-06
167. Evaluation of hypoallergenicity of an amino acid-based infant formula
#09.55 PED
168. A phase 2, multicenter, parallel-group, randomized, double-blind, placebo- and active comparator-controlled, combination study of S 555739 and Cetirizine HCl in adult patients with seasonal allergic rhinitis
#1210D1526
169. A double-blind, placebo-controlled, four-way crossover study to compare the safety and efficacy of ONO-6950 20 mg and 200 mg QD versus placebo and Montelukast (Singulair) in asthmatic patients who exercise-induced bronchoconstriction
#ONO6959POU004
170. ACQ, AQLQ, RQLQ Equivalence Study
#1788A
171. Asthma Control Diary (ACD) Equivalence Study
#1643A
172. A phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel group study of two doses of inhaled R940343 in patients with mild to moderate allergic asthma
#C-940343099
173. A multi-center, randomized, double-blind, vehicle-controlled, cross-over evaluation of the effects of KD1157 nasal spray on nasal challenge with allergen
#KD1157-AR02
174. A multi-center 52-week study to assess the safety of Albuterol *Spiromax*® in subjects with asthma
#ABS-AS-307

RESEARCH: ALEXANDER N. GREINER, MD

175. A randomized, placebo-controlled, Phase IIb dose-finding study of CYT003-QbG10, a TLR9-agonist, in patients with moderate to severe allergic asthma not sufficiently controlled on current standard therapy (GINA steps 3+4)
#CYT003-QbG10 12
176. A Prospective, Open label, Assessment of the Albuterol ProAir HFA MDI integrated dose counter
#ABM-AS-307
177. A 12-week Comparison of Efficacy and Safety of Albuterol Spiromax ® Versus Placebo in Subjects 12 years and older with Persistent Asthma
#ABS-AS-301
178. A Single-Dose Study to Assess the Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients with Exercise-Induced Bronchoconstriction (EIB)
#ABS-AS-302
179. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week, Clinical Study Designed to Assess the Efficacy and Safety of BDP Nasal Aerosol (80 mcg, once daily) in Pediatric Subjects (4 to 11 Years of Age) With Perennial Allergic Rhinitis (PAR)
#BDP-AR-306
180. A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily compared with Placebo in Adolescent and Adult Subjects with Severe Persistent Asthma Uncontrolled on Highdose Inhaled Corticosteroid Therapy
#FpS-AS-202
181. Validation of the Morning Symptom Diary in Patients with COPD: Assessing Content Validity through Concept Elicitation and Cognitive Interviewing
#M-12674
182. A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Cross-Over Evaluation of the Effects of KD1157 Nasal Spray on Nasal Challenge with Allergen
KD1157-AR02
183. A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study of JNJ-38518168 in Symptomatic Adult Subjects with Uncontrolled, Persistent Asthma
#38518168ASH2001
184. A Prospective, Open Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter
#ABS-AS-308
185. Double-blind, Placebo-Controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-Atopic, Asthmatic Patients with a Baseline, Pre-Bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled with Low Dose ICS Therapy
#CQAW039A2214A
186. A One-Year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects with House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis with or without Asthma
#P05607
187. A Randomized, Double-Blind, Multiple-Dose Trial of Mometasone Nasal Spray, 50 µg (Mylan), Nasonex® Nasal Spray, 50 µg (MSD-US), Nasonex® Nasal Spray Suspension, 50 µg (MSD-EU) and Placebo for the Treatment of the Signs and Symptoms of Seasonal Allergic Rhinitis in 1,520 Male and Female Volunteers

#MOMT-12084

188. A Phase III, Randomized, Double-Blind, Placebo-controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients with Uncontrolled Asthma who are on Inhaled Corticosteroids and a Second Controller Medication
#GB28688
189. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Adolescent and Adult Patients 12 Years of Age and Older with Persistent Asthma
#BDB-AS-301
190. A Randomized, Double Blind, Double Dummy, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered via Breath Actuated Inhaler (BAI) or Metered Dose Inhaler (MDI) in Pediatric Patients 5 Through 11 Years of Age with Persistent Asthma
#BDB-AS-302
191. A Randomized, Double Blind, Placebo Controlled, Parallel Group, 12 Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate (80 and 160 mcg/day) Delivered via Breath Actuated Inhaler (BAI) in Adolescent and Adult Patients 12 Years of Age and Older with Persistent Asthma
#BDB-AS-304
192. Oral Desensitization to Peanut in Peanut Allergic Children and Adults using Characterized Peanut Allergen (CPNA) Oral Immunotherapy (OIT)
#ARC001
193. Double-Blind, Randomized, Crossover Allergy Study of an Extensively Hydrolyzed Casein formula (NPS-G19A) Followed by a 16 Week Double Blind Feeding Period to Assess Growth, Safety and the Development of Tolerance to Cow's Milk Protein
#PRG-VA-14-001
194. A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older with Persistent Asthma.
#FSS-AS-305
195. Oral Desensitization to Peanut in Peanut-Allergic Children and Adults using Characterized Peanut Allergen (CPNA) Oral Immunotherapy (OIT) Safety Follow-On Study
#ARC002
196. A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects with a History of House Dust Mite-Induced Rhinoconjunctivitis
#TH005
197. A Randomized, Double-Blind, Double Dummy, Parallel Group Study to Determine the Local Equivalence of Multiple Doses of MGR001 to Advair® Diskus® Administered via Oral Inhalation in Adult Asthma Patients.
#MGR001-3001
198. Exploratory Evaluation of Nasal Strips in Children
#RH02599
199. Identification and Description of Severe Asthma Patients in a Cross-sectional Study--the IDEAL Study
#01